First tranche of $25 million available upon closing; the Company will be eligible to draw an additional $25 million subject to afami-cel approval

交割时可获得2500万美元的第一批资金；经afami cel批准，该公司将有资格再提取2500万美元

Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 15, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that it has entered into a $125 million five-year, term loan facility with Hercules Capital, Inc.

宾夕法尼亚州费城和联合王国牛津-（Newsfile Corp.-2024年5月15日）-Adaptimmune Therapeutics plc（纳斯达克股票代码：ADAP），一家重新定义用细胞疗法治疗实体瘤癌症的公司，今天宣布与Hercules Capital，Inc.签订了1.25亿美元的五年期定期贷款协议。

(NYSE: HTGC) ('Hercules'). The transaction strengthens the Company's balance sheet as it executes on its sarcoma franchise with the commercial launch of afami-cel later this year and lete-cel planned for 2026. The Company will host a live webcast at 8:00 a.m. EDT (1:00 p.m. BST) today to report its Q1 financial and business updates..

（纽约证券交易所：HTGC）（“大力神”）。随着今年晚些时候afami cel和lete cel计划于2026年商业上市，该交易加强了该公司的资产负债表，因为它正在执行其肉瘤特许经营权。该公司将于今天美国东部夏令时上午8:00（英国夏令时下午1:00）举行在线直播，报告其第一季度财务和业务最新情况。

Gavin Wood, Adaptimmune's Chief Financial Officer: 'We are focused on getting products to market starting with afami-cel later this year. We know that afami-cel has the potential to make a tremendous difference for people with sarcoma and we are pleased to partner with Hercules Capital in this transaction to strengthen our balance sheet.'.

Adaptimmune首席财务官加文·伍德（GavinWood）：“我们专注于从今年晚些时候的afami cel开始将产品推向市场。我们知道afami cel有可能为肉瘤患者带来巨大的改变，我们很高兴与Hercules Capital合作，以加强我们的资产负债表。”

R. Bryan Jadot – Senior Managing Director and Group Head at Hercules Capital: 'Hercules is excited to partner with Adaptimmune as they prepare to launch afami-cel and bring this therapy to patients living with synovial sarcoma. We are proud to support Adaptimmune's mission to design and deliver cell therapies to transform the lives of people with cancer.'.

R、 布莱恩·贾多特（BryanJadot）——大力士资本（Hercules Capital）高级常务董事兼集团负责人：“大力士很高兴与Adaptimmune合作，准备推出afami cel，并将这种疗法带给滑膜肉瘤患者。我们很自豪能够支持Adaptimmune设计和提供细胞疗法以改变癌症患者生活的使命。”

Jeffrey Ralto – Principal at Hercules Capital: 'We are proud to support Adaptimmune mission of developing and commercializing treatments for people with cancer. This financing should help support Adaptimmune's clinical and commercial strategies.'

赫拉克勒斯资本（Hercules Capital）负责人杰弗里·拉托（JeffreyRalto）：“我们很骄傲地支持Adaptimmune为癌症患者开发和商业化治疗的使命。这笔资金应该有助于支持Adaptimmune的临床和商业策略。”

The term loan facility provides for up to $125 million of term loans in aggregate, available in up to five tranches. Upon closing of the transaction, the first tranche of $25 million can be drawn. Under the terms of the agreement, Adaptimmune will be eligible to draw an additional tranche of $25 million upon afami-cel approval, and three additional tranches totaling $75 million over the medium-term subject to certain conditions..

定期贷款授信提供总计1.25亿美元的定期贷款，分五批提供。交易结束后，可提取首笔2500万美元。根据协议条款，Adaptimmune将有资格在afami cel批准后额外提取2500万美元，并根据某些条件在中期内提取三笔总计7500万美元的额外款项。

Additional details of the loan agreement will be filed with the Securities and Exchange Commission on a Current Report on Form 8-K.

贷款协议的其他详细信息将以表格8-K的最新报告提交给美国证券交易委员会。

TD Cowen acted as sole financial advisor to the Company. Ropes & Gray served as legal counsel to Adaptimmune and DLA Piper served as legal counsel to Hercules.

TD Cowen担任该公司的唯一财务顾问。罗普斯和格雷担任Adaptimmune的法律顾问，德拉·派珀担任大力士的法律顾问。

Today's Webcast Details for Adaptimmune's Q1 financial and business updates

今天的网络广播详细介绍了Adaptimmune第1季度的财务和业务更新

A live webcast and replay can be accessed at https://www.gowebcasting.com/13334. Call in information is as follows: 1-800-806-5484 (US or Canada) or +416-340-2217 (International and additional options available HERE) and the passcode is 3025919#. Callers should dial in 5-10 minutes prior to the scheduled start time and simply ask to join the Adaptimmune call..

您可以通过以下网址访问实时网络广播和重播：https://www.gowebcasting.com/13334.来电信息如下：1-800-806-5484（美国或加拿大）或+416-340-2217（此处提供国际和其他选项），密码为3025919#。呼叫者应在预定开始时间前5-10分钟拨入，只需请求加入Adaptimmune呼叫。

About Adaptimmune

关于Adaptimmune

Adaptimmune is a clinical-stage biopharmaceutical company focused on designing, developing, and delivering cell therapies to transform the lives of people with cancer. The Company's unique engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types..

Adaptimmune是一家临床阶段的生物制药公司，专注于设计，开发和提供细胞疗法，以改变癌症患者的生活。该公司独特的工程化T细胞受体（TCR）平台使T细胞的工程化能够靶向和破坏多种实体瘤类型的癌症。

Forward-Looking Statements

前瞻性声明

This release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes.

本版本包含《1995年私人证券诉讼改革法案》（PSLRA）所指的“前瞻性声明”。这些前瞻性陈述涉及某些风险和不确定性。此类风险和不确定性可能导致我们的实际结果与此类前瞻性声明所示的结果存在重大差异，包括但不限于：我们产品开发活动和临床试验的成功率、成本和时间安排，以及我们通过监管和商业化过程成功推进TCR治疗候选人的能力。

For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended 31 December, 2023, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission.

有关可能导致我们的实际结果与这些前瞻性声明中表达的结果存在重大差异的风险和不确定性的进一步描述，以及与我们的总体业务相关的风险，请参阅我们提交给美国证券交易委员会的表10-K年度报告 2023年12月，我们在表格10-Q上的季度报告，在表格8-K上的当前报告，以及向证券交易委员会提交的其他文件。

The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances..

本新闻稿中包含的前瞻性声明仅在声明发布之日起生效，我们没有义务更新此类前瞻性声明以反映后续事件或情况。